Xencor (XNCR) Goodwill & Intangibles (2013 - 2026)
Xencor (XNCR) posted quarterly Goodwill & Intangibles of $7.6 million for Q1 2026, down 43.11% year-over-year from $13.4 million in Q1 2025, and down 9.34% quarter-over-quarter from $8.4 million in Q4 2025.
Analysis
Xencor (XNCR) Goodwill & Intangibles (2013 - 2026) Analysis & Trends
Xencor (XNCR) has reported Goodwill & Intangibles for 14 consecutive years, with $7.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Goodwill & Intangibles fell 43.11% year-over-year to $7.6 million; the TTM figure through Mar 2026 stood at $7.6 million (down 43.11% YoY), while the FY2025 annual figure was $8.4 million, down 54.64% from the prior year.
- Goodwill & Intangibles eased to $7.6 million in Q1 2026 per XNCR's latest filing, from $8.4 million in the prior quarter.
- Across five years, Goodwill & Intangibles topped out at $18.9 million in Q1 2024 and bottomed at $7.6 million in Q1 2026.
- Historically, Goodwill & Intangibles has averaged $15.9 million across 5 years, with a median of $18.1 million in 2022.
- Annual changes were most pronounced in 2022 — Goodwill & Intangibles climbed 12.17% — and 2025, when it sank 54.64%.
- Xencor's Goodwill & Intangibles stood at $18.5 million in 2022, then climbed by 0.88% to $18.7 million in 2023, then retreated by 0.95% to $18.5 million in 2024, then tumbled by 54.64% to $8.4 million in 2025, then decreased by 9.34% to $7.6 million in 2026.
- Business Quant data shows XNCR's Goodwill & Intangibles at $7.6 million in Q1 2026, $8.4 million in Q4 2025, and $9.5 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Xencor | 2.02 Bn | 1.65 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 6.52 Mn |
| Mar 31, 2026 | 7.60 Mn |
| Dec 31, 2025 | 8.39 Mn |
| Sep 30, 2025 | 9.47 Mn |
| Jun 30, 2025 | 11.25 Mn |
| Mar 31, 2025 | 13.36 Mn |
| Dec 31, 2024 | 18.49 Mn |
| Sep 30, 2024 | 17.92 Mn |
| Jun 30, 2024 | 18.78 Mn |
| Mar 31, 2024 | 18.85 Mn |
| Dec 31, 2023 | 18.66 Mn |
| Sep 30, 2023 | 18.74 Mn |
| Jun 30, 2023 | 18.71 Mn |
| Mar 31, 2023 | 18.24 Mn |
| Dec 31, 2022 | 18.50 Mn |
| Sep 30, 2022 | 18.09 Mn |
| Jun 30, 2022 | 17.94 Mn |
| Mar 31, 2022 | 16.71 Mn |
| Dec 31, 2021 | 16.49 Mn |
| Sep 30, 2021 | 16.68 Mn |